Filing search / Inhibrx Biosciences, Inc. / "Audit"

DEFM14A

INBX Inhibrx Biosciences, Inc.

26 Apr 24

Proxy related to merger

4:06pm

-Closing Reorganization and the Distribution, including third-party legal, audit and advisory fees, and are being assumed by the Company as a result … of this Agreement, to the Company’s independent auditors and the audit committee of the Company Board of Directors (and made available to Parent a summary

DEFA14A

ucl6u

23 Jan 24

Additional proxy soliciting materials

6:38am

8-K

EX-2.1

m751uq1

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

76o9z6b xb6u5v7t7du

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-10.1

j71vidj

29 Aug 23

Inhibrx Announces $200 Million Private Placement Financing

9:03am